New anti-cancer news, what is the effect of cabozantinib on lung cancer patients?

Cabozantinib (Cabozantinib) is a small molecule tyrosine kinase inhibitor that selectively targets MET, VEGFR-2, RET, ROS1 and AXL and exhibits potent anti-ROS1 activity in many solid tumors, especially against those solvent frontier ROS1 resistance mutations, such as G2032R, D2033N, L1519R and L2026M. A Phase II trial of cabozantinib is currently underway. To date, there is no clinical evidence on the potential efficacy of cabozantinib in CD74-ROS1-positive NSCLC.

Previous preclinical studies in non-small cell lung cancer cell lines have shown that cabozantinib can effectively target wild-type and drug-resistant mutantsCD74-ROS1.5. The effectiveness of cabozantinib in treating lung cancer varies from person to person. Some clinical studies have shown that cabozantinib can prolong patient survival and slow tumor progression. However, every patient's situation is different, so the effectiveness of treatment will vary.

The original drug Cabozantinib is not marketed in the country and therefore cannot be included in medical insurance. The original cabozantinib drug marketed overseas includes Japanese, European and Turkish versions. The price of tablets may be more than 30,000 yuan, and the price of capsule preparations may be more than 40,000 yuan (prices may fluctuate due to exchange rates). There are also generic drugs produced in other countries overseas, and their pharmaceutical ingredients are basically the same as those of the original drugs. For example, the price of pharmaceuticals produced by Bangladeshi pharmaceutical factories may be more than 2,000 yuan (the price may fluctuate due to the exchange rate), which is relatively cheap.